TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed study drug treatment in parent study (VX18-445-104); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study~Key Exclusion Criteria:~* History of study drug intolerance in parent study~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Part A: Participants received ELX (elexacaftor) 200 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 96 weeks.~Part B: Participants from certain countries participated in Part B and continued to receive ELX 200 mg qd /TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Lira Pump Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes ≥ 1 year~* BMI \> 25 kg/m2~* Insulin pump ≥ 1 year~* HbA1c \> 58 mmol/mol~* Use of carbohydrate counting and the insulin pump bolus calculator~Exclusion Criteria:~* Gastroparesis~* Impaired renal function (eGFR \< 60 ml/min/1.73m2)~* Liver disease with ALAT \> 2.5 times the upper limit of the reference interval~* Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis~* Inflammatory bowel disease~* History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years~* Thyroid adenoma~* Subjects with personal or family history of MTC or MEN2~* Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start~* Known or suspected alcohol or drug abuse~* Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation~* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.~* Simultaneous participation in any other clinical intervention trial~* Known or suspected hypersensitivity to Liraglutide~* Inability to understand the patient information and to give informed consent~* Acute treatment required proliferative retinopathy or maculopathy (macular oedema)~* Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo; daily subcutaneous injection; 1.8 mg; 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed melanoma~  * Inoperable locally recurrent or metastatic disease~* Measurable disease~  * No lytic or blastic bone metastasis as only evidence of metastasis~ * Prior radiotherapy to a target lesion allowed provided there has been clear progression of disease since completion of radiotherapy~* No active brain metastasis, including leptomeningeal involvement~  * Prior brain metastasis allowed provided the disease is in complete remission for at least 1 month after therapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* More than 12 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~Hepatic~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis)~* Bilirubin ≤ 1.5 mg/dL~Renal~* Creatinine ≤ 1.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception 1 month before and during study participation~* No pre-existing peripheral neuropathy ≥ grade 2~* No prior allergy or hypersensitivity to study drug~* No concurrent clinically significant illness~* No other concurrent active malignancy~* No serious medical risk factors involving any of the major organ systems that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Recovered from prior chemotherapy~* More than 4 weeks since prior cytotoxic chemotherapy~* At least 3 weeks since prior anthracyclines~* No concurrent taxane or anthracyclines~* No concurrent doxorubicin~Endocrine therapy~* No concurrent steroids except as needed for hypersensitivity to study drug~Radiotherapy~* See Disease Characteristics~* Concurrent radiotherapy to a symptomatic non-target lesion (including recurrent or new brain metastases that develop during study participation) allowed~Surgery~* Not specified~Other~* More than 4 weeks since prior investigational drugs and recovered~* No other concurrent anticancer therapy~* No concurrent participation in another clinical study~* No other concurrent investigational therapies~* No concurrent ritonavir, saquinavir, indinavir, or nelfinavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of atopic dermatitis that has been clinically stable for ≥1 month~* Total body surface area (BSA) of atopic dermatitis involvement ≤35%, excluding involvement of the face, scalp, and groin~* Presence of two (2) comparable target lesions~* Willing and able to apply study medications as directed, comply with study instructions, and commit to attending all visits~* Females of childbearing potential must use at least one highly effective method of birth control. Males with partners of childbearing potential should inform them of their participation in this clinical study and use highly effective methods of birth control during the study.~Exclusion Criteria:~* Concurrent or recent use of certain topical or systemic medications or phototherapy without a sufficient washout period~* Active or potentially recurrent dermatologic condition other than atopic dermatitis in the target lesion area that may confound evaluation~* Significant confounding conditions as assessed by study doctor~* History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis)~* Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AN2898 ointment, 1%, vs. ointment vehicle (Type: EXPERIMENTAL): AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B.
- AN2728 ointment, 2%, vs. ointment vehicle (Type: EXPERIMENTAL): AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Esophageal erosions~* Retrosternal pyrosis lasting ≥ 3 months~* Pyrosis and/or regurgitation with a frequency ≥ 3 nights per week~* GERD-associated sleep disturbance (insomnia, poor sleep quality) lasting ≥ 1 month~* GERD-associated sleep disturbance (insomnia, poor sleep quality) with a frequency ≥ 3 nights per week~Exclusion Criteria:~* Non-erosive gastroesophageal reflux disease (NERD)~* Peptic ulcer~* History of upper gastrointestinal surgery (except for cholecystectomy)~* Lactating or pregnant women~* Nighttime shift workers (12 am to 6 am)~* Obstructive sleep apnea hypopnea syndrome~* Chronic obstructive pulmonary disease~* Patients with nocturnal supplementary oxygen requirement~* Orthopnea~* Restless legs syndrome~* Patients consuming more than 3 cups of coffee per day~* Patients planning to travel beyond 3 time zones during study~* Patients being treated with sleep medication (e.g. anxiolytics, antihistamines, benzodiazepines) for less than 3 months~* Patients being treated with sleep medication (e.g. anxiolytics, antihistamines, benzodiazepines), when suspension or dose modification of this drugs is being planned during the study course

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Head of bed elevation - Control (Type: OTHER): Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
- Control - Head of bed elevation (Type: OTHER): Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of Very long-chain acylCoA dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency, Mitochondrial Trifunctional Protein (TFP) Deficiency, or Long-chain 3 hydroxyacylCoA dehydrogenase (LCHAD) deficiency~* \> 7 years~* Ability to travel to CRC to participate~* Ability to follow protocol~Exclusion Criteria:~* Hgb \< 10 g/dl~* Peripheral neuropathy that limits ability to complete treadmill studies~* Inclusion in another research study that alters macronutrient intake~* Pregnant females~* history of myocardial infarction or cardiovascular disease

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medium Chain Triglyceride (MCT) (Type: ACTIVE_COMPARATOR): Subjects randomized to consume 20% of energy from MCT
- Triheptanoin (Type: EXPERIMENTAL): Subject randomized to consume 20% of energy from triheptanoin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 78 years of age~* Currently on metformin monotherapy~Exclusion Criteria:~* History of Type 1 diabetes mellitus or ketoacidosis~* Currently on a weight loss program and not in the maintenance phase or has started on a weight loss medication within the last 8 weeks~* Has undergone surgery requiring general anesthesia within the past 4 weeks or has planned major surgery~* Currently participating in a study or has participated in a study with or without an investigational compound or device within the past 12 weeks~* History of active liver disease such as chronic active hepatitis B or C, cirrhosis or symptomatic gallbladder disease~* HIV positive~* Pregnant, breast-feeding or planning to become pregnant during the study~* User of recreational or illicit drugs or has a recent history (within the past year) of drug or alcohol abuse or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Person-Centered Versus Measurement-Based Care in Mental Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and older~* Non-SMI (anxiety, post-traumatic stress disorder, depression, dysthymia, depression NOS) or SMI (schizophrenia, bipolar disorder, major depression)~* Receiving services at one of the 15 participating community mental health centers~* At least three claims for medication management services in past 12 months~* Insured by Community Care Behavioral Health Organization~Exclusion Criteria:~* Assessed by clinicians as being too ill to be treated on an outpatient basis~* Unable to speak, read, or understand English at the minimum required level

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Person-Centered Care (Type: ACTIVE_COMPARATOR): Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
- Measurement-Based Care (Type: ACTIVE_COMPARATOR): Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Selenium on Succinylcholine-Induced POM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult Patients aged 20-40 years, either sex.~* ASA physical status I or II.~* Elective sinuscopic procedures.~* Moderate to severe myalgia grade 2,3.~Exclusion Criteria:~* Abnormal renal and liver function tests.~* History of chronic pain, and regular medication with SNRI or analgesics (excluding acetaminophen and nonsteroidal anti-inflammatory drugs).~* patients with a history of seizure disorders, hyperkalemia, systemic illness like hypertension, diabetes, increased intracranial and intraocular pressure, pregnant or breast-feeding females.~* Any patients with previous history of drug induced muscle pain.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Group Placebo (Type: ACTIVE_COMPARATOR): 40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
- Group Selenium (Type: ACTIVE_COMPARATOR): 40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Superb Microvascular Imaging in Focal Nodular Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with biopsy or imaging proven focal nodular hyperplasia~Exclusion Criteria:~1. Pregnant women~2. Patient's age \> 70~3. Egg allergy~4. Breast-feeding women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SMI and sonazoid (single arm) (Type: EXPERIMENTAL): Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Evaluation of a Two and Three Piece Total Ankle Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (age \> 18 years) who will benefit from a total ankle replacement, as determined by Drs. Nunley, DeOrio, or Easley, with the aid of the physical exam and routine radiography treated at Duke University Medical Center and who have no medical conditions that would represent contraindications to surgery or anesthesia will be asked to participate in this study.~Exclusion Criteria:~* The only excluded patients will be those who do not choose to participate in this study, have a weight greater than 250lbs, or do not meet the minimum age of 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Salto Talaris Total Ankle Replacement (Type: OTHER): None
- STAR Total Ankle Replacement (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria:~Subjects aged 18 and over who meet criteria for OUDs based on the Structured Clinical Interview for DSM-5 (SCID) interview and are stable on medication treatment.~Exclusion Criteria:~1. Positive pregnancy test~2. Meningitis~3. Traumatic brain injury~4. Neurological disorder or organic mental disorder~5. History of loss of consciousness greater than one minute~6. Current pregnancy or breastfeeding for women~7. Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia, based on the SCID~8. A history of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness~9. Evidence of a major medical or neurological illness that is based on the clinical judgment of the study psychiatrist~10. Active implantable device (i.e. pacemaker)~11. Carotid atherosclerosis~12. Cervical vagotomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active non-invasive Vagal nerve stimulation (VNS) (Type: EXPERIMENTAL): Active non-invasive Vagal Nerve Stimulation (nVNS) with opioid cues.
- Sham stimulation (Type: SHAM_COMPARATOR): Sham stimulation of vagus with opioid cues

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete